Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00335777 · ClinicalTrials.gov registry record · Phase 4
A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine
A Phase 4 study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
NCT00335777 is a Phase 4 study that has completed, run by Thomas Jefferson University. The registered enrollment target is 64 participants.
The verdict
NCT00335777, a Phase 4 study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a research study looking at Migranal (study drug) in the treatment of two migraine attacks in patients who have a history of cutaneous allodynia (pronounced q-tay-nee-us al-o-din-ee-a). Cutaneous allodynia is an increased skin sensitivity experienced during a headache. It has been noted in several studies that in patients with migraine, seventy nine percent of the patients experienced allodynia on the facial skin on the same side as the headache. Understanding more about allodynia may help us understand how the pain system works in migraine. This study will compare the differences, if any, in attacks treated early with study drug (at 1-hour from onset) and attacks treated later (at 4-hours). You will be asked to treat one attack early and one attack late for this study. If the first attack you treat is early (at 1 hour following onset of throbbing pain) then the second attack you treat should be late (at 4 hours following onset of throbbing pain). It is hoped that this study will provide information on the use of Migranal in subjects who have cutaneous allodynia. The results from this study may be used in the development of larger clinical trials. The study drug is a medication that is taken in the form of nasal spray.
Interventions
- DRUG Migranal nasal spray at 1 hour
- DRUG Migranal nasal spray at 4 hour
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2006-08 |
| Est. Completion | 2009-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00335777
The ClinicalTrials.gov registry entry for NCT00335777 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Migranal nasal spray at 1 hour is the first listed.
NCT00335777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00335777 about?
NCT00335777 is a clinical study titled "A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine". This is a research study looking at Migranal (study drug) in the treatment of two migraine attacks in patients who have a history of cutaneous allodynia (pronounced q-tay-nee-us al-o-din-ee-a). Cutaneous allodynia is an increased skin sensitivity experienced during a headache. It has been noted in s...
What is the current status of trial NCT00335777?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2006-08. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00335777?
The interventions under investigation include: Migranal nasal spray at 1 hour (DRUG), Migranal nasal spray at 4 hour (DRUG).
Who is sponsoring clinical trial NCT00335777?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.